Taylor Sexton | Executive Director
Medical Countermeasures Coaltion

Taylor Sexton, Executive Director, Medical Countermeasures Coaltion

Taylor joined Todd Strategy Group in 2021 after serving as a Senior Advisor to the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services. He served in this role through two administrations and the COVID-19 pandemic. He also maintained his role as public health faculty and assistant director of federal affairs for Texas A&M University. While at HHS he advised the ASPR on many critical issues including the development and execution of Operation Warp Speed. As an infectious disease epidemiologist, he responded on behalf of the ASPR to coordinate state efforts, distribute therapeutics, acquire critical clinical supplies, and oversaw infection control within vaccine facilities. Taylor also served HHS as the Deputy Director of the HHS Joint Information Center (JIC) where he led a team to coordinate response within the interagency.

Before joining HHS and Texas A&M University Taylor worked for Chairman Michael Burgess, MD overseeing the reauthorization of the Pandemic All Hazards Act (PAHPA). Prior to this role he practiced epidemiology for one of the largest health departments in the country leading zoonotic and High Consequence Infectious Disease (HCID) surveillance. Through this role he was recognized by the American College of Obstetrics and Gynecology for a top cited article on infant outcomes of Zika evaluating both diagnostics and surveillance.

Taylor has a Master’s in Public Health (MPH) from the University of North Texas Health Science Center and a B.S. from Texas A&M University. He is adjunct public health faculty at Texas A&M University and maintains his board certification by the National Board of Public Health Examiners.


Day 3 - November 30 @ 08:40

Keynote Panel: Beyond Borders: Collaborating for success in developing vaccines for emerging infectious diseases

  • Challenges around stock piling vaccines that are not yet licensed – 
    • need for (relatively small) stockpiles of “vialed and quality-tested vaccines that are ready to be clinically tested in populations as soon as the next outbreak strikes”.
    • Is stockpiling the victim of market failure?
    • Funding mechanisms decoupled from the market
  • Aligning programmatic interests during outbreaks and “peace times
    • Experiences getting Sudan Ebola vaccines to Uganda
  • Alternative regulatory pathways and accelerated development
  • Aligning interests & objectives of international funding partners

Day 3 - November 30 @ 11:10

Chair's Opening Remarks

Day 3 - November 30 @ 11:15

Panel: De-risking therapeutics drug development for infectious diseases –

  • Road to repurposing and expanding use of broad-spectrum antivirals
  • Setting up public private partnerships
  • Alignment of interests
  • Commercial risks of clinical trials
last published: 02/Jan/24 12:15 GMT

back to speakers